Definitive Diagnostics
Definitive Diagnostics is developing a blood test platform to improve the reliability and affordability of cancer detection. Their mission is to target gaps in cancer care by enhancing the accuracy and cost-effectiveness of cancer detection for millions of patients, aiming to accelerate timely diagnoses and reduce waste from false test results. The company utilizes a patented, protein-based method that measures discovered biomarker patterns to detect cancer at its earliest stages, including Stage 0 for breast cancer and Stage I for lung, colorectal, ovarian, and pancreatic cancers. They are integrating AI with their protein platform to improve performance and discover new patterns for earlier diagnosis. The technology measures 16 biomarker parameters in blood, reporting 99% sensitivity across target cancers (including Stages 0, I), 97-99% specificity, and 98% Tissue of Origin accuracy. Their platform can also rule out false positives from mammograms or LD-CT scans with 98% accuracy and differentiate cancer subtypes like SCLC from NSCLC, and serous from mucinous ovarian cancers.
Definitive Diagnostics
Definitive Diagnostics is developing a blood test platform to improve the reliability and affordability of cancer detection. Their mission is to target gaps in cancer care by enhancing the accuracy and cost-effectiveness of cancer detection for millions of patients, aiming to accelerate timely diagnoses and reduce waste from false test results. The company utilizes a patented, protein-based method that measures discovered biomarker patterns to detect cancer at its earliest stages, including Stage 0 for breast cancer and Stage I for lung, colorectal, ovarian, and pancreatic cancers. They are integrating AI with their protein platform to improve performance and discover new patterns for earlier diagnosis. The technology measures 16 biomarker parameters in blood, reporting 99% sensitivity across target cancers (including Stages 0, I), 97-99% specificity, and 98% Tissue of Origin accuracy. Their platform can also rule out false positives from mammograms or LD-CT scans with 98% accuracy and differentiate cancer subtypes like SCLC from NSCLC, and serous from mucinous ovarian cancers.